CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on developing a new treatment for insulin deficiency, a condition caused by the loss of pancreatic beta cells. The aim is to improve patient outcomes by reducing insulin dosage while addressing related health risks associated with insulin therapy.
Tens of millions suffer from insulin deficiency (ID); a condition caused by pancreatic β-cell loss.
If untreated, ID is a lethal catabolic disease characterized by hyperglycemia.
Thus, the focus of ID research and drug development has been mainly on improving strategies to lower hyperglycemia without causing life-threatening hypoglycemia.
However, in addition to increased circulating glucose level β-cell loss leads to several “other defects”, some of which (e.g. severe hyperketonemia and ketoaci…
UNIVERSITE DE GENEVE
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
